RE:G12D/G12V KRAS mutation in PC & CRC patients respond to Pela One of the things that makes pancreatic cancers so hard to treat is that the tumor cells create a dense web of proteins and noncancerous cells around them. This web, which is part of what is called the tumor microenvironment, helps the tumor cells grow and impairs the immune system’s ability to attack them.
When a treatment is highly effective in killing tumor cells, “you usually trigger some sort of remodeling of the tumor microenvironment as well as changes in the immune cells that are part of the microenvironment,” and enlisting the immune system to attack tumors, means that combining pelareorep with immune checkpoint inhibitors—which help T cells kill cancer cells—makes the CPI more effective,.
And that is exciting because checkpoint inhibitors generally don’t work well [by themselves] in pancreatic cancer.
[ONCYs pelareorep as demonstrated it ability to remodel the tumor microenvironmet (TME) and along with multiple other actions including g12d/g12v targeting, allow cancer-fighting immune cells called T cells to be trafficked into the tumors.]
https://www.cancer.gov/news-events/cancer-currents-blog/2023/pancreatic-cancer-kras-g12d-mrtx1133#:~:text=However%2C%20some%20mutant%20forms%20of,in%20several%20other%20cancer%20types.